Create a free Feed Strategy account to continue reading

Boehringer Ingelheim to invest in avian vaccines

Six months after inaugurating its new French animal health headquarters in the heart of the Lyon-Gerland Biodistrict, Boehringer Ingelheim has confirmed its allegiance to the region by announcing that it is about to invest a further EUR65 million in the metropolitan area.

Six months after inaugurating its new French animal health headquarters in the heart of the Lyon-Gerland Biodistrict, Boehringer Ingelheim has confirmed its allegiance to the region by announcing that it is about to invest a further EUR65 million (US$80.2 million) in the metropolitan area.

The German group has laid the first stone of a 5,700 square meter building at its Lyon Porte-des-Alpes (LPA) site. Known as F2IVE (Formulation and Filling of Inactivated Vaccines Extension), this major project will comprise a three-story building - including 1,000 square meters of clean room space – mainly for formulating and distributing avian vaccines.

“As poultry consumption continues to rise around the world, there is an increasing demand for avian vaccines. This meant that our LPA production site in Saint-Priest was going to reach a saturation point by 2020. We had to do some forward planning and find additional production capacity,” explained Erick Lelouche, President of Boehringer Ingelheim Animal Health France.